Myricanol prevents aging-related sarcopenia by rescuing mitochondrial dysfunction via targeting peroxiredoxin 5

Area of Science:

• Gerontology and Molecular Biology
• Muscle Physiology and Aging Research

Background:

• Aging involves molecular and cellular damage, increasing disease risk like sarcopenia.
• Sarcopenia, characterized by muscle wasting, severely impacts mobility, quality of life, and increases fall risks in the elderly.
• Mitochondrial dysfunction due to oxidative damage is a key factor in age-related muscle loss.

Purpose of the Study:

• To investigate the protective effects of myricanol (MY) against age-related muscle wasting in mice.
• To determine if MY alleviates oxidative damage in mitochondria and identify its direct protein target and mechanism of action.

Main Methods:

• Administration of myricanol (MY) to aged mice to assess its impact on muscle mass and strength.
• Biophysical assays to identify the direct protein target of MY.
• Experiments using C2C12 myotubes to evaluate MY's effect on reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) damage.

Main Results:

• Myricanol (MY) protected aged mice from muscle mass and strength decline.
• MY effectively scavenged reactive oxygen species (ROS), restoring redox homeostasis.
• Peroxiredoxin 5 (Prx5) was identified as the direct target of MY.
• Activation of Prx5 by MY reduced ROS accumulation and damaged mitochondrial DNA in muscle cells.

Conclusions:

• Myricanol (MY) demonstrates therapeutic potential for sarcopenia by mitigating oxidative damage and improving mitochondrial function.
• Targeting peroxiredoxin 5 (Prx5) with MY offers a novel strategy for combating age-related muscle wasting.
• These findings contribute to understanding healthy aging and developing interventions for age-related diseases.